Delaware top court will hear drugmakers' appeal to end Zantac lawsuits-July 2024-www.financetom.com

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Aug 27, 2024 11:20 PM

Aug 27 (Reuters) - Delaware's highest court said on

Tuesday it will hear an appeal by GSK and other

drugmakers seeking to end more than 70,000 lawsuits claiming

discontinued heartburn drug Zantac caused cancer.

GSK, Pfizer ( PFE ), Sanofi and Boehringer

Ingelheim are asking the court to overturn an order by a lower

court judge allowing plaintiffs in the lawsuits to offer expert

testimony on the alleged cancer link. The companies have denied

the allegations.

Previous page： Blue Bird Insider Sold Shares Worth $767,260, According to a Recent SEC Filing Next page： Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Blue Bird Insider Sold Shares Worth $767,260, According to a Recent SEC Filing

Sep 2, 2025

11:25 AM EDT, 09/02/2025 (MT Newswires) -- Phil Horlock, Director, on August 28, 2025, sold 13,000 shares in Blue Bird ( BLBD ) for $767,260. Following the Form 4 filing with the SEC, Horlock has control over a total of 240,766 common shares of the company, with 240,766 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1589526/000157947725000018/xslF345X05/wk-form4_1756826178.xml Price: 57.75, Change: -0.64, Percent Change:...

Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal

Sep 2, 2025

Nukkleus Inc. ( NUKK ) shares soared on Tuesday after the company said it will acquire Israel-based Tiltan Software Engineering Ltd. in a $14 million deal. The acquisition, to be paid in a mix of cash and stock, is expected to close following regulatory approval and audited financials. The announcement underscores growing demand for AI-powered simulation and GPS-denied navigation tools...

Update: Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia

Sep 2, 2025

11:26 AM EDT, 09/02/2025 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.) Ionis Pharmaceuticals ( IONS ) shares were up more than 33% in recent Tuesday trading after the company reported topline data from phase 3 studies of olezarsen, which showed that the drug candidate significantly reduced fasting triglycerides and acute pancreatitis events in...

Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced

Sep 2, 2025

11:25 AM EDT, 09/02/2025 (MT Newswires) -- (Updates to include Arrowhead's stock movement in the headline and the first paragraph.) Arrowhead Pharmaceuticals ( ARWR ) shares rose 9.2% in recent Tuesday trading after the company announced a global licensing and collaboration agreement for its ARO-SNCA preclinical stage siRNA therapy to treat synucleinopathies, including Parkinson's disease, with Novartis ( NVS )...